Three drug regimens offer modest survival in patients with R/R DLBCL
Three anticancer drug regimens deliver moderate survival benefits to patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL), particularly between the last treatment course and death, according to a study.